Eph receptors and ephrins: Therapeutic opportunities

Annual Review of Pharmacology and Toxicology

Volumn 55, Issue , 2015, Pages 467-487

  Barquilla, Antonio ^a   Pasquale, Elena B ^a,b  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Cancer; Neurological disease; Tyrosine kinase; Viral infection

Indexed keywords

EPHRIN; EPHRIN RECEPTOR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARDIOVASCULAR AGENT; LIGAND;

ALZHEIMER DISEASE; ANGIOGENESIS; BRAIN CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CARDIOVASCULAR SYSTEM; CELL COMMUNICATION AND CELL CONTACT; CLINICAL TRIAL (TOPIC); HEART FUNCTION; HUMAN; LUNG CANCER; NERVE DEGENERATION; NERVE REGENERATION; NERVOUS SYSTEM; NEUROLOGIC DISEASE; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TOXICITY; TUMOR MICROENVIRONMENT; VIRUS INFECTION; ANIMAL; CARDIOVASCULAR DISEASES; DRUG DESIGN; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NERVOUS SYSTEM DISEASES; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; VIROLOGY; VIRUS DISEASES;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG DESIGN; EPHRINS; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NERVOUS SYSTEM DISEASES; RECEPTORS, EPH FAMILY; SIGNAL TRANSDUCTION; VIRUS DISEASES;

EID: 84920811328     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011112-140226     Document Type: Review

References (172)

1. Pasquale EB. 2005. Eph receptor signalling casts a wide net on cell behaviour. Nat. Rev. Mol. Cell Biol. 6:462-75
2. Pasquale EB. 2008. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133:38-52
3. Batlle E, Wilkinson DG. 2012. Molecular mechanisms of cell segregation and boundary formation in development and tumorigenesis. Cold Spring Harb. Perspect. Biol. 4:a008227
4. Pasquale EB. 2010. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 10:165-80
5. Goldshmit Y, McLenachan S, Turnley A. 2006. Roles of Eph receptors and ephrins in the normal and damaged adult CNS. Brain Res. Rev. 52:327-45
6. Arvanitis DN, Davy A. 2012. Regulation and misregulation of Eph/ephrin expression. Cell Adhes. Migr. 6:131-37
7. Sugiyama N, Gucciardo E, Tatti O, Varjosalo M, Hyytiainen M, et al. 2013. EphA2 cleavage by MT1- MMP triggers single cancer cell invasion via homotypic cell repulsion. J. Cell Biol. 201:467-84
8. Lisabeth EM, Falivelli G, Pasquale EB. 2013. Eph receptor signaling and ephrins. Cold Spring Harb. Perspect. Biol. 5:a009159
9. Pitulescu ME, Adams RH. 2010. Eph/ephrinmolecules- A hub for signaling and endocytosis. Genes Dev. 24:2480-92
10. Binda E, Visioli A, Giani F, Lamorte G, Copetti M, et al. 2012. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22:765-80
11. Hwang YS, Lee HS, Kamata T, Mood K, Cho HJ, et al. 2013. The Smurf ubiquitin ligases regulate tissue separation via antagonistic interactions with ephrinB1. Genes Dev. 27:491-503
12. Choi KM, Park GL, Hwang KY, Lee JW, Ahn HJ. 2013. Efficient siRNA delivery into tumor cells by p19-YSA fusion protein. Mol. Pharm. 10:763-73
13. Daar IO. 2012. Non-SH2/PDZ reverse signaling by ephrins. Semin. Cell Dev. Biol. 23:65-74
14. Wykosky J, Debinski W. 2008. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol. Cancer Res. 6:1795-806
15. Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W. 2012. EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Mol. Cell. Biol. 32:3253-64
16. Falivelli G, Lisabeth EM, Rubio de la Torre E, Perez-Tenorio G, Tosato G, et al. 2013. Attenuation of Eph receptor kinase activation in cancer cells by coexpressed ephrin ligands. PLOS ONE 8:e81445
17. Janes PW, Nievergall E, Lackmann M. 2012. Concepts and consequences of Eph receptor clustering. Semin. Cell Dev. Biol. 23:43-50
18. Truitt L, Freywald A. 2011. Dancingwith the dead: Eph receptors and their kinase-null partners. Biochem. Cell Biol. 89:115-29
19. Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, et al. 2011. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLOS ONE 6:e17649
20. Argenzio E, Bange T, Oldrini B, Bianchi F, Peesari R, et al. 2011. Proteomic snapshot of the EGFinduced ubiquitin network. Mol. Syst. Biol. 7:462
21. Bouche E, Romero-Ortega MI, Henkemeyer M, Catchpole T, Leemhuis J, et al. 2013. Reelin induces EphB activation. Cell Res. 23:473-90
22. Miao H, Li DQ, Mukherjee A, Guo H, Petty A, et al. 2009. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16:9-20
23. Astin JW, Batson J, Kadir S, Charlet J, Persad RA, et al. 2010. Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells. Nat. Cell Biol. 12:1194-204
24. Theus MH, Ricard J, Glass SJ, Travieso LG, Liebl DJ. 2014. EphrinB3 blocks EphB3 dependence receptor functions to prevent cell death following traumatic brain injury. Cell Death Dis. 5:e1207
25. Bochenek ML, Dickinson S, Astin JW, Adams RH, Nobes CD. 2010. Ephrin-B2 regulates endothelial cell morphology and motility independently of Eph-receptor binding. J. Cell Sci. 123:1235-46
26. Senturk A, Pfennig S, Weiss A, Burk K, Acker-Palmer A. 2011. Ephrin Bs are essential components of the Reelin pathway to regulate neuronal migration. Nature 472:356-60
27. Genet G, Guilbeau-Frugier C, Honton B, Dague E, Schneider MD, et al. 2012. Ephrin-B1 is a novel specific component of the lateral membrane of the cardiomyocyte and is essential for the stability of cardiac tissue architecture cohesion. Circ. Res. 110:688-700
28. Arvanitis D, Davy A. 2008. Eph/ephrin signaling: networks. Genes Dev. 22:416-29
29. Hruska M, Dalva MB. 2012. Ephrin regulation of synapse formation, function and plasticity. Mol. Cell Neurosci. 50:35-44
30. Du J, Fu C, Sretavan DW. 2007. Eph/ephrin signaling as a potential therapeutic target after central nervous system injury. Curr. Pharm. Des. 13:2507-18
31. Vasileiou I, Adamakis I, Patsouris E, Theocharis S. 2013. Ephrins and pain. Expert Opin. Ther. Targets 17:879-87
32. Funk SD, Orr AW. 2013. Ephs and ephrins resurface in inflammation, immunity, and atherosclerosis. Pharmacol. Res. 67:42-52
33. Coulthard MG, Morgan M, Woodruff TM, Arumugam TV, Taylor SM, et al. 2012. Eph/ephrin signaling in injury and inflammation. Am. J. Pathol. 181:1493-503
34. Sheffler-Collins SI, Dalva MB. 2012. EphBs: an integral link between synaptic function and synaptopathies. Trends Neurosci. 35:293-304
35. Chen Y, Fu AK, Ip NY. 2012. Eph receptors at synapses: implications in neurodegenerative diseases. Cell Signal. 24:606-11
36. Noberini R, Lamberto I, Pasquale EB. 2012. Targeting Eph receptors with peptides and small molecules: progress and challenges. Semin. Cell Dev. Biol. 23:51-57
37. Tognolini M, Hassan-Mohamed I, Giorgio C, Zanotti I, Lodola A. 2013. Therapeutic perspectives of Eph-ephrin system modulation. Drug Discov. Today 19:661-69
38. Harrison C. 2014. Patents related to EPH receptors and ligands. Nat. Rev. Drug Discov. 13:13
39. Boyd AW, Bartlett PF, Lackmann M. 2014. Therapeutic targeting of EPH receptors and their ligands. Nat. Rev. Drug Discov. 13:39-62
40. Conway A, Vazin T, Spelke DP, Rode NA, Healy KE, et al. 2013. Multivalent ligands control stem cell behaviour in vitro and in vivo. Nat. Nanotechnol. 8:831-38
41. Goldshmit Y, Spanevello MD, Tajouri S, Li L, Rogers F, et al. 2011. EphA4 blockers promote axonal regeneration and functional recovery following spinal cord injury in mice. PLOS ONE 6:e24636
42. Fabes J, Anderson P, Brennan C, Bolsover S. 2007. Regeneration-enhancing effects of EphA4 blocking peptide following corticospinal tract injury in adult rat spinal cord. Eur. J. Neurosci. 26:2496-505
43. Spanevello MD, Tajouri SI, Mirciov C, Kurniawan N, Pearse MJ, et al. 2013. Acute delivery of EphA4-Fc improves functional recovery after contusive spinal cord injury in rats. J. Neurotrauma 30:1023-34
44. Kempf A, Montani L, Petrinovic MM, Schroeter A, Weinmann O, et al. 2013. Upregulation of axon guidance molecules in the adult central nervous system of Nogo-A knockout mice restricts neuronal growth and regeneration. Eur. J. Neurosci. 38:3567-79
45. Munro KM, Perreau VM, Turnley AM. 2012. Differential gene expression in the EphA4 knockout spinal cord and analysis of the inflammatory response following spinal cord injury. PLOS ONE 7:e37635
46. Duffy P, Wang X, Siegel CS, Tu N, Henkemeyer M, et al. 2012. Myelin-derived ephrinB3 restricts axonal regeneration and recovery after adult CNS injury. Proc. Natl. Acad. Sci. USA 109:5063-68
47. Ren Z, Chen X, Yang J, Kress BT, Tong J, et al. 2013. Improved axonal regeneration after spinal cord injury in mice with conditional deletion of ephrin B2 under the GFAP promoter. Neuroscience 241:89-99
48. Van Hoecke A, Schoonaert L, Lemmens R, Timmers M, Staats KA, et al. 2012. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat. Med. 18:1418-22
49. Overman JJ, Clarkson AN, Wanner IB, Overman WT, Eckstein I, et al. 2012. A role for ephrin-A5 in axonal sprouting, recovery, and activity-dependent plasticity after stroke. Proc. Natl. Acad. Sci. USA 109:E2230-39
50. Lemmens R, Jaspers T, Robberecht W, Thijs VN. 2013. Modifying expression of EphA4 and its downstream targets improves functional recovery after stroke. Hum. Mol. Genet. 22:2214-20
51. Cisse M, Halabisky B, Harris J, Devidze N, Dubal DB, et al. 2011. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469:47-52
52. Vargas LM, Leal N, Estrada LD, Gonzalez A, Serrano F, et al. 2014. EphA4 activation of c-Abl mediates synaptic loss and LTP blockade caused by amyloid-beta oligomers. PLOS ONE 9:e92309
53. Fu AK, Hung KW, Huang H, Gu S, Shen Y, et al. 2014. Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimers disease. Proc. Natl. Acad. Sci. USA 111:9959-64
54. Lai WB, Wang BJ, Hu MK, Hsu WM, Her GM, Liao YF. 2014. Ligand-dependent activation of EphA4 signaling regulates the proteolysis of amyloid precursor protein through a Lyn-mediated pathway. Mol. Neurobiol. 49:1055-68
55. Matsui C, Inoue E, Kakita A, Arita K, Deguchi-Tawarada M, et al. 2012. Involvement of the γ-secretasemediated EphA4 signaling pathway in synaptic pathogenesis of Alzheimers disease. Brain Pathol. 22:776-87
56. Barthet G, Dunys J, Shao Z, Xuan Z, Ren Y, et al. 2013. Presenilin mediates neuroprotective functions of ephrinB and brain-derived neurotrophic factor and regulates ligand-induced internalization and metabolism of EphB2 and TrkB receptors. Neurobiol. Aging 34:499-510
57. Schellenberg GD, Montine TJ. 2012. The genetics and neuropathology of Alzheimers disease. Acta Neuropathol. 124:305-23
58. Lin L, Lesnick TG, Maraganore DM, Isacson O. 2009. Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics. Trends Neurosci. 32:142-49
59. Jing X, Miwa H, Sawada T, Nakanishi I, Kondo T, et al. 2012. Ephrin-A1-mediated dopaminergic neurogenesis and angiogenesis in a rat model of Parkinsons disease. PLOS ONE 7:e32019
60. Cibert-Goton V, Yuan G, Battaglia A, Fredriksson S, Henkemeyer M, et al. 2013. Involvement of EphB1 receptors signalling in models of inflammatory and neuropathic pain. PLOS ONE 8:e53673
61. Leandro-Garcia LJ, Inglada-Perez L, Pita G, Hjerpe E, Leskela S, et al. 2013. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J. Med. Genet. 50:599-605
62. Cruz-Orengo L, Figueroa JD, Velazquez I, Torrado A, Ortz C, et al. 2006. Blocking EphA4 upregulation after spinal cord injury results in enhanced chronic pain. Exp. Neurol. 202:421-33
63. Kuijper S, Turner CJ, Adams RH. 2007. Regulation of angiogenesis by Eph-ephrin interactions. Trends Cardiovasc. Med. 17:145-51
64. Stephen LJ, Fawkes AL, Verhoeve A, Lemke G, Brown A. 2007. A critical role for the EphA3 receptor tyrosine kinase in heart development. Dev. Biol. 302:66-79
65. Frieden LA, Townsend TA, Vaught DB, Delaughter DM, Hwang Y, et al. 2010. Regulation of heart valve morphogenesis by Eph receptor ligand, ephrin-A1. Dev. Dyn. 239:3226-34
66. Salvucci O, Tosato G. 2012. Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv. Cancer Res. 114:21-57
67. Jellinghaus S, Poitz DM, Ende G, Augstein A, Weinert S, et al. 2013. Ephrin-A1/EphA4-mediated adhesion of monocytes to endothelial cells. Biochim. Biophys. Acta 1833:2201-11
68. Miao H, Wang B. 2012. EphA receptor signaling-complexity and emerging themes. Semin. Cell Dev. Biol. 23:16-25
69. Wu Z, Luo H, Thorin E, Tremblay J, Peng J, et al. 2012. Possible role of Efnb1 protein, a ligand of Eph receptor tyrosine kinases, in modulating blood pressure. J. Biol. Chem. 287:15557-69
70. Brantley-Sieders DM, Chen J. 2004. Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis 7:17-28
71. Biao-Xue R, Xi-Guang C, Shuan-Ying Y, Wei L, Zong-Juan M. 2011. EphA2-dependent molecular targeting therapy for malignant tumors. Curr. Cancer Drug Targets 11:1082-97
72. Nakayama M, Nakayama A, van Lessen M, Yamamoto H, Hoffmann S, et al. 2013. Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat. Cell Biol. 15:249-60
73. Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, et al. 2010. Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. Am. J. Pathol. 176:2029-38
74. Li JL, Sainson RC, Oon CE, Turley H, Leek R, et al. 2011. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 71:6073-83
75. Goichberg P, Bai Y, DAmario D, Ferreira-Martins J, Fiorini C, et al. 2011. The ephrin A1-EphA2 system promotes cardiac stem cell migration after infarction. Circ. Res. 108:1071-83
76. Goichberg P, Kannappan R, Cimini M, Bai Y, Sanada F, et al. 2013. Age-associated defects in EphA2 signaling impair the migration of human cardiac progenitor cells. Circulation 128:2211-23
77. Dries JL, Kent SD, Virag JA. 2011. Intramyocardial administration of chimeric ephrinA1-Fc promotes tissue salvage following myocardial infarction in mice. J. Physiol. 589:1725-40
78. Mansson-Broberg A, Siddiqui AJ, Genander M, Grinnemo KH, Hao X, et al. 2008. Modulation of ephrinB2 leads to increased angiogenesis in ischemic myocardium and endothelial cell proliferation. Biochem. Biophys. Res. Commun. 373:355-59
79. Ishii M, Mueller I, Nakajima T, Pasquale EB, Ogawa K. 2011. EphB signaling inhibits gap junctional intercellular communication and synchronized contraction in cultured cardiomyocytes. Basic Res. Cardiol. 106:1057-68
80. Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, et al. 2013. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 3:1302-15
81. Lisabeth EM, Fernandez C, Pasquale EB. 2012. Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry 51:1464-75
82. Zhuang G, Song W, Amato K, Hwang Y, Lee K, et al. 2012. Effects of cancer-associated EPHA3 mutations on lung cancer. J. Natl. Cancer Inst. 104:1182-97
83. Udayakumar D, Zhang G, Ji Z, Njauw CN, Mroz P, Tsao H. 2011. EphA2 is a critical oncogene in melanoma. Oncogene 30:4921-29
84. Lu M, Miller KD, Gokmen-Polar Y, Jeng M-H, Kinch MS. 2003. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res. 63:3425-29
85. Gokmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, et al. 2011. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Res. Treat. 127:375-84
86. Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, et al. 2010. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 70:299-308
87. Stahl S, Kaminskyy VO, Efazat G, Hyrslova Vaculova A, Rodriguez-Nieto S, et al. 2013. Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412. Cell Death Dis. 4:e454
88. Nakada M, Hayashi Y, Hamada J. 2011. Role of Eph/ephrin tyrosine kinase in malignant glioma. Neuro Oncol. 13:1163-70
89. Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, et al. 2013. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 23:238-48
90. Miao H, Gale NW, Guo H, Qian J, Petty A, et al. 2014. EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene. In press. doi: 10. 1038/onc. 2013. 590
91. Yang NY, Fernandez C, Richter M, Xiao Z, Valencia F, et al. 2011. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cell Signal. 23:201-12
92. Wang SD, Rath P, Lal B, Richard JP, Li Y, et al. 2012. EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. Oncogene 31:5132-43
93. Ying Z, Li Y, Wu J, Zhu X, Yang Y, et al. 2013. Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. Cancer Res. 73:990-99
94. Johnson RA, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D, et al. 2010. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466:632-36
95. Li JJ, Xie D. 2013. The roles and therapeutic potentials of Ephs and ephrins in lung cancer. Exp. Cell Res. 319:152-59
96. Saintigny P, Peng S, Zhang L, Sen B, Wistuba II, et al. 2012. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol. Cancer Ther. 11:2021-32
97. Song W, Ma Y, Wang J, Brantley-Sieders D, Chen J. 2014. JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. Cancer Res. 74:2444-54
98. Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, et al. 2014. Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. J. Clin. Investig. 124:2037-49
99. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-75
100. Ji XD, Li G, Feng YX, Zhao JS, Li JJ, et al. 2011. EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res. 71:1156-66
101. Li G, Ji XD, Gao H, Zhao JS, Xu JF, et al. 2012. EphB3 suppresses non-small-cell lung cancermetastasis via a PP2A/RACK1/Akt signalling complex. Nat. Commun. 3:667
102. Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, et al. 2013. The EphB4 receptor tyrosine kinase promotes lung cancer growth: A potential novel therapeutic target. PLOS ONE 8:e67668
103. Bulk E, Yu J, Hascher A, Koschmieder S, Wiewrodt R, et al. 2012. Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer. PLOS ONE 7:e44591
104. Thanapprapasr D, Hu W, Sood AK, Coleman RL. 2012. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr. Pharm. Des. 18:2713-19
105. Heroult M, Schaffner F, Pfaff D, Prahst C, Kirmse R, et al. 2010. EphB4 promotes site-specificmetastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2. Mol. Cancer Res. 8:1297-309
106. Xu K, Broder CC, Nikolov DB. 2012. Ephrin-B2 and ephrin-B3 as functional henipavirus receptors. Semin. Cell Dev. Biol. 23:116-23
107. Dewannieux M, Vernochet C, Ribet D, Bartosch B, Cosset FL, Heidmann T. 2011. The mouse IAPE endogenous retrovirus can infect cells through any of the five GPI-anchored Ephrin A proteins. PLOS Pathog. 7:e1002309
108. Chakraborty S, Veettil MV, Bottero V, Chandran B. 2012. Kaposis sarcoma-associated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection. Proc. Natl. Acad. Sci. USA 109:E1163-72
109. Hahn AS, Kaufmann JK, Wies E, Naschberger E, Panteleev-Ivlev J, et al. 2012. The ephrin receptor tyrosine kinase A2 is a cellular receptor forKaposis sarcoma-associated herpesvirus. Nat. Med. 18:961-66
110. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, et al. 2011. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 17:589-95
111. Chen W, Sin SH, Wen KW, Damania B, Dittmer DP. 2012. Hsp90 inhibitors are efficacious against Kaposi sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLOS Pathog. 8:e1003048
112. Karlas A, Machuy N, Shin Y, Pleissner KP, Artarini A, et al. 2010. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 463:818-22
113. Genander M, Frisen J. 2010. Ephrins and Eph receptors in stem cells and cancer. Curr. Opin. Cell Biol. 22:611-16
114. Matsuo K, Otaki N. 2012. Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases. Cell Adhes. Migr. 6:148-56
115. Lin S, Wang B, Getsios S. 2012. Eph/ephrin signaling in epidermal differentiation and disease. Semin. Cell Dev. Biol. 23:92-101
116. Gordon K, Kochkodan JJ, Blatt H, Lin SY, Kaplan N, et al. 2013. Alteration of the EphA2/ephrin-A signaling axis in psoriatic epidermis. J. Investig. Dermatol. 133:712-22
117. Genander M, Holmberg J, Frisen J. 2010. Ephrins negatively regulate cell proliferation in the epidermis and hair follicle. Stem Cells 28:1196-205
118. Szepietowska B, Zhu W, Czyzyk J, Eid T, Sherwin RS. 2013. EphA5-EphrinA5 interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local glutamine/glutamate balance during hypoglycemia. Diabetes 62:1282-88
119. Jain R, Jain D, Liu Q, Bartosinska B, Wang J, et al. 2013. Pharmacological inhibition of Eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets. Diabetologia 56:1350-55
120. Zhang R, Zhong NN, Liu XG, Yan H, Qiu C, et al. 2010. Is the EFNB2 locus associated with schizophrenia? Single nucleotide polymorphisms and haplotypes analysis. Psychiatry Res. 180:5-9
121. Shi S, Liu J, Joshi SB, Krasnoperov V, Gill P, et al. 2012. Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. J. Pharm. Sci. 101:1969-84
122. Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, et al. 2010. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer 10:641
123. Brar M, Cheng L, Yuson R, Mojana F, Freeman WR, Gill PS. 2010. Ocular safety profile and intraocular pharmacokinetics of an antagonist of EphB4/EphrinB2 signalling. Br. J. Ophthalmol. 94:1668-73
124. Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, et al. 2009. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 113:254-63
125. Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, et al. 2011. The eph-receptor a7 is a soluble tumor suppressor for follicular lymphoma. Cell 147:554-64
126. Zisch AH, Zeisberger SM, Ehrbar M, Djonov V, Weber CC, et al. 2004. Engineered fibrin matrices for functional display of cell membrane-bound growth factor-like activities: study of angiogenic signaling by ephrin-B2. Biomaterials 25:3245-57
127. Saik JE, Gould DJ, Keswani AH, Dickinson ME, West JL. 2011. Biomimetic hydrogels with immobilized ephrinA1 for therapeutic angiogenesis. Biomacromolecules 12:2715-22
128. Lee HY, Mohammed KA, Peruvemba S, Goldberg EP, Nasreen N. 2011. Targeted lung cancer therapy using ephrinA1-loaded albumin microspheres. J. Pharm. Pharmacol. 63:1401-10
129. Lohmuller T, Triffo S, ODonoghue GP, Xu Q, Coyle MP, Groves JT. 2011. Supported membranes embedded with fixed arrays of gold nanoparticles. Nano Lett. 11:4912-18
130. Shaw A, Lundin V, Petrova E, F ord . os F, Benson E, et al. 2014. Spatial control of membrane receptor function using ligand nanocalipers. Nat. Methods 11:841-46
131. Kiewlich D, Zhang J, Gross C, Xia W, Larsen B, et al. 2006. Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. Neoplasia 8:18-30
132. Coffman KT, Hu M, Carles-Kinch K, Tice D, Donacki N, et al. 2003. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res. 63:7907-12
133. Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, et al. 2010. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol. Ther. 10:1306-14
134. Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, et al. 2009. Antibodydependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia 11:509-17
135. Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, et al. 2010. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin. Cancer Res. 16:2562-70
136. Abengozar MA, de Frutos S, Ferreiro S, Soriano J, Perez-Martinez M, et al. 2012. Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood 119:4565-76
137. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, et al. 2010. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol. Cancer Ther. 9:2377-88
138. Lamberto I, Qin H, Noberini R, Premkumar L, Bourgin C, et al. 2012. Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor. Biochem. J. 445:47-56
139. Koolpe M, Burgess R, Dail M, Pasquale EB. 2005. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J. Biol. Chem. 280:17301-11
140. Duggineni S, Mitra S, Lamberto I, Han X, Xu Y, et al. 2013. Design and synthesis of potent bivalent peptide agonists targeting the EphA2 receptor. ACS Med. Chem. Lett. 4:344-48
141. Noberini R, Mitra S, Salvucci O, Valencia F, Duggineni S, et al. 2011. PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity. PLOS ONE 6:e28611
142. Zhang R, Xiong C, Huang M, Zhou M, Huang Q, et al. 2011. Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts. Biomaterials 32:5872-79
143. Wang S, Noberini R, Stebbins JL, Das S, Zhang Z, et al. 2013. Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin. Cancer Res. 19:128-37
144. Mitra S, Duggineni S, Koolpe M, Zhu X, Huang Z, Pasquale EB. 2010. Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry 49:6687-95
145. Wang S, Placzek WJ, Stebbins JL, Mitra S, Noberini R, et al. 2012. Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. J. Med. Chem. 55:2427-36
146. Duggineni S, Mitra S, Noberini R, Han X, Lin N, et al. 2013. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4. Biochem. Pharmacol. 85:507-13
147. Wu B, Zhang Z, Noberini R, Barile E, Giulianotti M, et al. 2013. HTS by NMR of combinatorial libraries: A fragment-based approach to ligand discovery. Chem. Biol. 20:19-33
148. Incerti M, Tognolini M, Russo S, Pala D, Giorgio C, et al. 2013. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J. Med. Chem. 56:2936-47
149. Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, et al. 2014. Crosstalk between EphA2 and BRaf/CRaf is a key determinant of response to dasatinib. Clin. Cancer Res. 20:1846-55
150. Martiny-Baron G, Holzer P, Billy E, Schnell C, Brueggen J, et al. 2010. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis 13:259-67
151. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, et al. 2010. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465:483-86
152. Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, et al. 2013. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin. Cancer Res. 19:1806-15
153. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, et al. 2009. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol. Ther. 8:1027-34
154. Jackson D, Gooya J, Mao S, Kinneer K, Xu L, et al. 2008. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 68:9367-74
155. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, et al. 2009. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 101:1193-205
156. Cai W, Ebrahimnejad A, Chen K, Cao Q, Li ZB, et al. 2007. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur. J. Nucl. Med. Mol. Imaging 34:2024-36
157. Wang JL, Liu YL, Li Y, Dai WB, Guo ZM, et al. 2012. EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats. Investig. Ophthalmol. Vis. Sci. 53:7348-57
158. Dickerson EB, Blackburn WH, Smith MH, Kapa LB, Lyon LA, McDonald JF. 2010. Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer 10:10
159. Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, et al. 2005. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents. Cancer Res. 65:6745-54
160. Gobin AM, Moon JJ, West JL. 2008. EphrinA1-targeted nanoshells for photothermal ablation of prostate cancer cells. Int. J. Nanomedicine 3:351-58
161. Mao W, Luis E, Ross S, Silva J, Tan C, et al. 2004. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res. 64:781-88
162. Li D, Liu S, Liu R, Zhou Y, Park R, et al. 2013. EphB4-targeted imaging with antibody h131, h131- F(ab-)2 and h131-Fab. Mol. Pharm. 10:4527-33
163. Liu S, Li D, Park R, Liu R, Xia Z, et al. 2013. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies. J. Nucl. Med. 54:1094-100
164. You J, Zhang R, Xiong C, Zhong M, Melancon M, et al. 2012. Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res. 72:4777-86
165. Huang M, Xiong C, Lu W, Zhang R, Zhou M, et al. 2014. Dual-modality micro-positron emission tomography/computed tomography and near-infrared fluorescence imaging of EphB4 in orthotopic glioblastoma xenograft models. Mol. Imaging Biol. 16:74-84
166. You J, Wang Z, Du Y, Yuan H, Zhang P, et al. 2013. Specific tumor delivery of paclitaxel using glycolipidlike polymer micelles containing gold nanospheres. Biomaterials 34:4510-19
167. Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, et al. 2013. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol. Ther. 21:629-37
168. Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, et al. 2007. Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct. Cancer Res. 67:3927-35
169. Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, et al. 2013. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Investig. New Drugs 31:77-84
170. Ieguchi K, Tomita T, Omori T, Komatsu A, Deguchi A, et al. 2014. ADAM12-cleaved ephrin-A1 contributes to lung metastasis. Oncogene 33:2179-90
171. Dong Y, Harrington BS, Adams MN, Wortmann A, Stephenson SA, et al. 2014. Activation of membranebound proteins and receptor systems: A link between tissue kallikrein and the KLK-related peptidases. Biol. Chem. 395:977-90
172. Ji YJ, Hwang YS, Mood K, Cho HJ, Lee HS, et al. 2014. EphrinB2 affects apical constriction in Xenopus embryos and is regulated by ADAM10 and flotillin-1. Nat. Commun. 5:3516